Economic Observer Follow
2026-11-20 18:21

In early October, Zhao Zhang was diagnosed with a recurrence of diffuse large B-cell lymphoma (DLBCL), and the attending physician suggested that he might try CAR-T (chimeric antigen receptor T cell) therapy.
The attending physician said that CAR-T therapy is more effective in second-line treatment (treatment after lymphoma recurrence) - with a 5-year disease-free survival rate higher than conventional chemotherapy therapy. ”Zhao Zhang told reporters.
However, the cost of CAR-T therapy exceeds one million yuan, which is an insurmountable hurdle for the vast majority of families.
Lymphoma is one of the common malignant tumors in the blood system. According to the data released by the National Cancer Center, the incidence rate of lymphoma in China is about 6.68/100000, with an annual growth rate of 3% -5%. Every year, there are about 100000 new patients. Among them, diffuse large B-cell lymphoma is the most common type of adult non Hodgkin lymphoma, accounting for about 30% to 40% of all adult cases. Clinical studies have shown that about 40% of DLBCL patients still face disease recurrence after undergoing first-line treatment.
The insurance market for the healthy population is approaching saturation, and insurance companies are turning to developing related products for patients in order to find new opportunities for premium growth. For example, for lymphoma patients, Zhong'an Online has launched the Zhongminbao · Relapse Insurance (Lymphoma Plan), covering 8 subtypes including diffuse large B-cell lymphoma, classical Hodgkin lymphoma, follicular lymphoma, etc; Ping An Property and Casualty Insurance, in collaboration with Chenxi Health and Fosun Carey, has launched the "Ping An Medical Worry Free · Yilin Ankang Lymphoma Recurrence Medical Insurance" with a coverage of 900000 yuan, of which 700000 yuan will be used to pay for CAR-T drug Akilensai Injection (Yikaida) ®)。
In the past, when facing the health insurance group, insurance companies could exclude high-risk individuals from coverage through health information and physical examinations, thereby reducing the burden of claims; And this type of lymphoma specific medical insurance mainly targets lymphoma patients, whose probability of pathological claims is much higher than that of healthy individuals. How to avoid loss of control in claims has become a serious challenge for insurance companies.
Unbearable exorbitant treatment costs
Cheng Haixin is the deputy chief physician of the oncology department at a tertiary hospital in Shanghai. In the past year, he has treated over 150 patients with recurrent lymphoma.
Cheng Haixin said that if the patient's family has certain financial resources and is willing to spend a lot of money on treatment, he will recommend the patient to try CAR-T therapy.
Our oncology department's clinical data shows that the 5-year disease-free survival rate of lymphoma recurrence patients receiving CAR-T therapy is more than 20 percentage points higher than conventional chemotherapy, and can basically reach over 60%. ”Cheng Haixin told reporters. However, among over 150 relapsed lymphoma patients, only a few ultimately chose to receive CAR-T therapy. For example, in the face of a treatment cost of over 1.2 million yuan, 98% of patients have given up on the CAR-T therapy with Akilensai injection.
Zhao Zhang has not yet made a decision on whether to accept CAR-T therapy. Although his family has repeatedly stated that they no longer care about money, as long as they are alive, everything will get better, he still wants to leave the family savings to his wife and children.
The attending physician asked me to make a decision as soon as possible, because the longer the illness drags on, the worse it will be for my health, "Zhao Zhang said. Recently, he joined a group of over 130 lymphoma recurrence patients and plans to seek opinions from other patients. When it comes to the cost of CAR-T therapy, the vast majority of patients in the group feel that they really don't have the financial ability.
Zhao Zhang once hoped that insurance could share the cost of CAR-T treatment. He consulted with the insurance agent about the possibility of purchasing "million dollar medical insurance", but was informed that the coverage of this insurance is limited to healthy individuals.
So, he turned his hopes to Huiminbao, which he purchased earlier this year. The personnel of Huimin Factoring Compensation Institution informed that according to the current Huimin Factoring Compensation terms in the local area, the compensation rate for lymphoma recurrence patients using CAR-T therapy is 30% - if Zhao Zhang uses Yikaida ® Treatment, Huimin Insurance can only reimburse about 360000 yuan. This means that he still needs to bear the cost of over 800000 yuan of treatment at his own expense.
The reporter learned that some insurance companies have previously launched "efficacy insurance", which means that if the insured person uses CAR-T therapy at their own expense and fails to achieve the expected efficacy, the insurance company will compensate about 50% of the CAR-T treatment cost.
Zhao Zhang said that this type of insurance belongs to post event economic compensation products and may not effectively reduce the actual economic burden of CAR-T therapy for lymphoma recurrence patients. Moreover, most patients with recurrent lymphoma cannot afford treatment costs exceeding one million yuan.
Zhang Shijie is the chief expert of Chenxi Health's specialized disease insurance team, who has been tracking the treatment status of lymphoma recurrence patients for a long time. He told reporters that more than half of lymphoma recurrence patients can afford treatment costs between 200000 and 300000 yuan, which is a significant gap from the expenditure of CAR-T therapy.
The gap in coverage for patients has also become an opening for insurance companies to develop cancer recurrence insurance.
Reshaping the Insurance Underwriting and Compensation Mechanism
However, compared to insurance products for healthy individuals, the difficulty of developing cancer recurrence insurance is much higher.
For the same million yuan coverage, the million yuan medical insurance is aimed at the healthy population, and can significantly reduce the proportion of million yuan claims cases through the law of large numbers and actuarial probability of claims. However, the lymphoma recurrence insurance faces policyholders who have a 40% probability of disease recurrence and have a history of illness, which puts a lot of pressure on claims management and risk control, "said Zhang Shijie.
Zhang Shijie said that every policyholder's lymphoma recurrence means that the insurance company needs to pay a claim amount of 900000 yuan. Therefore, the biggest concern for insurance companies is the loss of control of claims - once the claim cases far exceed expectations, the insurance company will fall into a huge underwriting loss situation.
Therefore, insurance companies need to collect as much clinical data as possible from lymphoma recurrence patients, combined with lymphoma pathological subtypes, high-risk factors (such as TP53 mutations), and other factors, to construct corresponding user screening categories and strict underwriting and claims risk control mechanisms, in order to achieve sustainable product operation.
Zhang Shijie said that by collecting a large amount of clinical data from lymphoma recurrence patients for actuarial analysis, the lymphoma recurrence insurance he participated in the research and development of is limited to lymphoma recurrence patients who have achieved CR (complete remission) or partial remission (PR) in the mid-term evaluation, and the premium is set differently based on the IPI (International Lymphoma Prognostic Index, usually between 0-5 points, with higher scores indicating higher recurrence risk) score.
In addition to the above indicators, we also need to conduct a comprehensive evaluation based on the past chemotherapy and radiotherapy status of lymphoma recurrence patients, and ultimately decide whether to insure, "said Zhang Shijie. The current lymphoma recurrence insurance can cover about 10% of lymphoma recurrence patients. If the claims ratio (the proportion of claims cases to underwriting cases) can be controlled at 2% to 4%, it is expected to find a balance between sustainable insurance and reducing the economic burden of more patients using CAR-T therapy.
The ability to obtain a large amount of clinical data from lymphoma patients for risk control actuarial claims is also a challenge for Jiang Ying. She is the Product Innovation Director of the Health Insurance Department at a large insurance company.
At the beginning of this year, she started developing a lymphoma recurrence medical insurance. During this period, the risk control department of the insurance company repeatedly mentioned whether the health insurance department has sufficient comprehensive and rich clinical data for actuarial purposes, ensuring that the claims ratio is controlled at a reasonable level.
Due to concerns about incomplete data leading to claims being out of control, the senior management of Jiang Ying's insurance company requested that she redesign the insurance terms to ensure that the product coverage does not incur losses.
In addition to the actuarial challenges of collecting and analyzing clinical data from patients, another key to the sustainable operation of lymphoma specific medical insurance lies in whether the product can quickly form premium scale effects and improve claims ability.
Through market research, Zhang Shijie found that most lymphoma patients are willing to pay an annual premium of 10000 to 20000 yuan, but the prerequisite is that the insurance company can quickly complete the claims and pay the CAR-T treatment fees in a timely manner.
At present, Jiang Ying is developing a full course medical insurance only for patients with diffuse large B-cell lymphoma, and also includes innovative therapies such as CAR-T in the scope of claims.
She believes that if the underwriting target is limited to a specific lymphoma disease group, the relevant clinical data acquisition and actuarial calculation will be more focused, which will also help improve the overall risk control level of claims and achieve the goal of product underwriting without losses.